Back to GetFilings.com

Table of Contents

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

For the quarterly period ended March 31, 2003

OR

For the transition period from         to        

Commission file number 0-14068

Memry Corporation

(Exact name of registrant as specified in its charter)

(203) 739-1100

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No ¨

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

As of May 9, 2003, 25,525,295 shares of the registrant’s common stock, par value $.01 per share, were issued and outstanding.

Table of Contents

INDEX

2

Table of Contents

PART I — FINANCIAL INFORMATION

ITEM 1.    Financial Statements

Memry Corporation & Subsidiaries

Consolidated Balance Sheets

See Notes to Consolidated Financial Statements

3

Table of Contents

Memry Corporation & Subsidiaries

Consolidated Statements of Income

For the Three Months Ended March 31, 2003 and 2002

(Unaudited)

See Notes to Consolidated Financial Statements

4

Table of Contents

Memry Corporation & Subsidiaries

Consolidated Statements of Income

For the Nine Months Ended March 31, 2003 and 2002

(Unaudited)

See Notes to Consolidated Financial Statements

5

Table of Contents

Memry Corporation & Subsidiaries

Consolidated Statements of Cash Flows

For the Nine Months Ended March 31, 2003 and 2002

(Unaudited)

See Notes to Consolidated Financial Statements

6

Table of Contents

MEMRY CORPORATION & SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note A.  BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation, have been included. Operating results for the nine month period ended March 31, 2003, are not necessarily indicative of the results that may be expected for the year ending June 30, 2003 (“fiscal 2003”). For further information, refer to the consolidated financial statements and footnotes thereto included in the Annual Report on Form 10-K for the year ended June 30, 2002 (“fiscal 2002”) of Memry Corporation (the “Company”).

Note B.  INVENTORIES

Inventories at March 31, 2003, and June 30, 2002, are summarized as follows:

Note C.  NOTE RECEIVABLE - RELATED PARTY

On August 29, 2000, the Company made a loan to an executive officer which has been collateralized by his personal residence. The loan was part of the executive officer’s overall compensation package and was to be forgiven, providing certain conditions were met, over a four year period. During 2001, the executive officer was terminated and the note became current at that time. The terms of the note have subsequently been amended such that the note, in the amount of $110,000, is now due on Jan 28, 2005, or at such time that the residence is sold, whichever occurs first.

Note D.  ACCRUED EXPENSES

Accrued Expenses at March 31, 2003 and June 30, 2002 are summarized as follows:

Note E.  EARNINGS PER SHARE

Basic earnings per share amounts are computed by dividing net income by the weighted-average number of common shares outstanding. Diluted per share amounts assume exercise of all potential common stock instruments unless the effect is to reduce the loss or increase the income per common share.

For the periods presented, there were no items which changed net income as presented in the consolidated statements of income and the amounts used to compute basic and diluted earnings per share. The following is information about the computation of weighted-average shares utilized in the computation of basic and diluted earnings per share.

7

Table of Contents

Note F.  INCOME TAXES

A reconciliation of the anticipated income tax provision (computed by applying the statutory Federal income tax rate (34%) to income before income taxes) to the income tax provision (benefit) as reported in the statements of income are as follows:

As of March 31, 2003, the Company had net operating loss carryforwards of approximately $16,451,000 available to reduce future Federal taxable income, which expire in 2005 through 2011.

Note G.  STOCK COMPENSATION PLANS

Statement of Financial Accounting Standards (SFAS) No. 123, “Accounting for Stock-Based Compensation”, encourages all entities to adopt a fair value based method of accounting for employee stock compensation plans, whereby compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. However, it also allows an entity to continue to measure compensation cost for those plans using the intrinsic value based method of accounting prescribed by Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees,” whereby compensation cost is the excess, if any, of the quoted market price of the stock at the grant date (or other measurement date) over the amount an employee must pay to acquire the stock. Stock options issued to employees and directors under the Company’s stock option and warrant plans have no intrinsic value at the grant date, and under Opinion No. 25 no compensation cost is recognized for them. On January 1, 2003, the Company adopted SFAS No. 148, “Accounting for Stock-Based Compensation – Transition and Disclosure, an Amendment of FASB Statement No. 123.” The Company has elected to continue with the accounting methodology in Opinion No. 25 and, as a result, has provided pro forma disclosures of net income and earnings per share and other disclosures, as if the fair value based method of accounting had been applied.

Had compensation cost for issuance of such options and warrants been recognized based on the fair values of awards on the grant dates, in accordance with the method described in SFAS No. 123, reported net income and per share amounts for 2003 and 2002 would have been decreased (increased) to the pro forma amounts shown below:

8

Table of Contents

ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF                    OPERATIONS

The following is management’s discussion and analysis of certain significant factors that have affected the Company’s financial position and operating results. Certain statements under this caption may constitute “forward-looking statements”. See Part II — “Other Information”.

(a)     RESULTS OF OPERATIONS

Three Months Ended March 31, 2003, compared to Three Months Ended March 31, 2002.

Revenues.   In the past several years, the Company has focused on increasing the amount of value-added products it provides to the marketplace, i.e., products where additional processing is performed on basic nitinol wire, strip, or tube before it is shipped to the customer. Currently, medical device applications represent some of the best opportunities for increasing the amount of value-added business. The kink-resistant and self-expanding properties of nitinol have made peripheral stenting an area of special interest, and stent components manufactured for Abdominal Aortic Aneurysms (AAA) in particular have become a significant driver of the Company’s revenue. However, because the market for stent components is very dynamic and rapidly changing, the Company has found it difficult to accurately forecast demand for its stent components. Delays in product launches, uncertain timing on regulatory approvals, inventory adjustments by our customers, market share shifts between competing stent platforms and the introduction of next-generation products have all contributed to the variability in revenue generated by shipments of medical stent components.

Revenues increased 13% to $8,460,000 in the third quarter of fiscal 2003 from $7,519,000 during the same period in fiscal 2002, an increase of $941,000. Shipments of wire-based medical stent components decreased approximately $100,000 in the third quarter of fiscal 2003 compared to the third quarter of fiscal 2002 and tube-based medical stent components increased approximately $1,200,000 in the third quarter of fiscal 2003 compared to the third quarter of fiscal 2002. Looking forward, the Company anticipates that overall AAA stent component activity for the next six months will reflect a significant decrease from the shipment levels of the second and third quarters of fiscal 2003. The Company also anticipates that increased competition in superelastic tube supply will put pressure on prices in selected segments of the business.

Other medical device component shipments, including products utilized in minimally invasive surgery and guidewire applications, increased approximately $400,000 in the third quarter of fiscal 2003 compared to the third quarter of fiscal 2002.

Revenues from sales of arch wire and high pressure sealing plugs decreased approximately $150,000 during the third quarter of fiscal 2003 compared to the third quarter of fiscal 2002.

Revenue from semi-finished material shipments also decreased in the third quarter of fiscal 2003 versus the third quarter of fiscal 2002. Shipments of superelastic tube, utilized in coronary applications and for other peripheral stenting, decreased approximately

9

Table of Contents

$300,000 and superelastic wire, utilized in various industrial applications, decreased $120,000. The Company anticipates that increasing competition will put pressure on pricing for superelastic tube during the balance of fiscal 2003 and fiscal 2004.

Costs and Expenses.  Manufacturing costs (including costs associated with research and development revenues) increased to $5,734,000 for the three months ended March 31, 2003 from $4,788,000 during the same three month period in fiscal 2002, an increase of $946,000, or 20%. A portion of this increase is explained by the 13% increase in revenue. In addition, there was a shift in product mix, including a smaller percentage of high margin superelastic tube, and higher product costs in eastern operations due to unfavorable plant absorption.

Because of the foregoing, the Company’s gross margin from sales decreased to 32% for the three month period ended March 31, 2003, from 36% in the comparable period in fiscal 2002. The Company does not anticipate improvement in gross margins for the next six to nine months due to a weak forecast for AAA stent component demand and the resultant negative impact on manufacturing plant absorption and competitive pricing pressure on certain segments of the superelastic tube business.

General, selling and administrative expenses (including depreciation and amortization) decreased $198,000, or 8%, to $2,269,000 for the three months ended March 31, 2003, as compared to $2,467,000 during the same period of fiscal 2002. This decrease is primarily due to a reduction in consulting, bonus accrual and legal costs. The Company incurred research and development expenses of $631,000 relating to its own internal products as well as the development of future products for the three months ended March 31, 2003 as compared to $708,000 incurred during the same period of fiscal 2002. Other expense decreased from $29,000 in the third quarter of fiscal 2002 to $14,000 in the comparable period in fiscal 2003, due primarily to an increase in interest income associated with a higher cash balance along with a reduction in interest expense associated with a reduced level of borrowing.

The Company recorded a provision for income taxes of $166,000 for the third quarter of fiscal 2003 versus a tax benefit of ($8,000) for the same period in fiscal 2002. This change is due primarily to an increase in deferred tax expense associated with the utilization of net operating loss carryforwards during the third quarter of fiscal 2003. In addition, there was a favorable retroactive IRS tax ruling in the same period of fiscal 2002.

Net Income.  Primarily due to a decrease in general, selling and administrative expenses, substantially offset by an increase in the provision for income taxes, the Company’s net income increased by $34,000, to $277,000 in the third quarter of fiscal 2003 compared to a net income of $243,000 for the same period in fiscal 2002.

Nine Months Ended March 31, 2003, compared to Nine Months Ended March 31, 2002.

Revenues.   Revenues increased 13% to $26,752,000 in the first nine months of fiscal 2003 from $23,717,000 during the same period in fiscal 2002, an increase of $3,035,000. Shipments of wire-based medical stent components increased approximately $2,500,000 in the nine month period ended March 31, 2003 compared to the nine month period ended March 31, 2002 and tube-based medical stent components increased approximately $1,100,000 in the nine month period ended March 31, 2003 compared to the same period in fiscal 2002. Looking forward, the Company anticipates that overall AAA stent component activity for the next six months will reflect a significant decrease from the shipment levels of the second and third quarters of fiscal 2003.

Other medical device component shipments, including products utilized in minimally invasive surgery and guidewire applications, increased approximately $1,400,000 in the first nine months of fiscal 2003 compared to the first nine months of fiscal 2002.

Revenues from sales of arch wire and high pressure sealing plugs increased approximately $600,000 during the first nine months of fiscal 2003 compared to the same period in fiscal 2002.

These revenue increases were partially offset by a decrease of approximately $1,800,000 in shipments of superelastic tube, utilized in coronary applications and for other peripheral stenting, and a decrease of $700,000 in superelastic wire, utilized in various industrial applications. The Company anticipates that increasing competition will put pressure on pricing for superelastic tube during the balance of fiscal 2003 and fiscal 2004. The Company also anticipates that increased competition in superelastic tube supply will put pressure on prices in selected segments of the business.

Costs and Expenses.   Manufacturing costs (including costs associated with research and development revenues) increased to $17,612,000 for the nine months ended March 31, 2003 compared to $12,932,000 during the same nine-month period in fiscal 2002. This increase of $4,680,000, or 36%, is the result of several factors. Part of the increase is explained by the 13% increase in revenue. In addition, the Company has experienced poor manufacturing yields in both its wire and tube based AAA stent component business in the first nine months of fiscal 2003 compared to the first nine months of fiscal 2002. Also, there has been

10

Table of Contents

a significant reduction in the percentage of high margin superelastic tube in the product mix that has had a negative impact on margins in fiscal 2003 versus fiscal 2002.

Because of the foregoing, the Company’s gross margin from sales decreased to 34% for the nine month period ended March 31, 2003, from 45% in the comparable period in fiscal 2002. The Company does not anticipate improvement in gross margins for the next six to nine months due to a weak forecast for AAA stent component demand and the resultant negative impact on manufacturing plant absorption and competitive pricing pressure on certain segments of the superelastic tube business.

General, selling and administrative expenses (including depreciation, amortization and a gain on disposal of assets) decreased $619,000, or 8%, to $7,036,000 for the nine months ended March 31, 2003, as compared to $7,655,000 during the same period of fiscal 2002. This decrease is primarily due to a reduction in consulting, bonus accrual and legal costs. The Company incurred research and development expenses of $1,847,000 relating to its own internal products as well as the development of future products for the nine months ended March 31, 2003 as compared to $1,981,000 during the same period of fiscal 2002. Other expense decreased from $105,000 in the first nine months of fiscal 2002 to $54,000 in the comparable period in fiscal 2003, due primarily to an increase in interest income associated with a higher cash balance along with a reduction in interest expense associated with a reduced level of borrowing.

The Company recorded a tax benefit of ($6,742,000) for the first nine months of fiscal 2003 versus a provision of $284,000 for the same period in fiscal 2002. This change is due primarily to a decrease in the deferred tax valuation allowance during the second quarter of fiscal 2003 to recognize deferred tax assets at amounts considered by management, more likely than not, to be realized.

Net Income.  Primarily due to the federal tax benefit and the reduction in operating expenses, the Company’s net income increased by $6,051,000, to $8,792,000 for the first nine months of fiscal 2003 compared to a net income of $2,741,000 for the same period in fiscal 2002. Excluding the recognition of the deferred tax asset of $6,877,000, net income for the nine month period ended March 31, 2003 was $1,915,000, compared to a net income of $2,741,000 for the nine month period ended March 31, 2002. Memry’s management believes that this non-GAAP measure (reversing the effect of the recognition of the deferred tax asset) is useful to investors because it allows comparisons to prior periods, and management uses the measure for such purpose.

(b)  LIQUIDITY AND CAPITAL RESOURCES

At March 31, 2003, the Company’s cash and cash equivalents balance was $5,361,000, an increase of $2,410,000 from $2,951,000 at the start of fiscal 2003. Cash provided by operations was $3,803,000 for the nine months ended March 31, 2003. Cash used in investing activities was $1,111,000 for the nine month period ended March 31, 2003, representing funds invested in property, plant and equipment. During the nine months ended March 31, 2003, cash used in financing activities totaled $282,000, reflecting principally the pay-down of the Company’s note payable. Working capital at March 31, 2003, was $12,451,000, an increase of $3,572,000 from $8,879,000 at June 30, 2002. $1,279,000 of the increase in working capital was represented by the current portion of the deferred tax asset that was recognized as of March 31, 2003.

In fiscal 2002 and the first nine months of fiscal 2003, ended on March 31, 2003, the primary capital requirement was to fund additions to property, plant and equipment.

On April 2, 2002, New England Partners exercised 200,000 warrants at a price of $0.853 per warrant, and 400,000 warrants at $1.19 per warrant, to purchase 600,000 shares of common stock of the Company. The Company received $647,000 from this transaction.

On March 31, 2002, a former employee exercised 125,000 warrants at a price of $.90 per warrant, to purchase 125,000 shares of common stock of the Company. The Company received $113,000 from this transaction.

On November 8, 2001, the Company completed a private equity placement with New England Partners and raised $750,000. Proceeds were raised through the sale of units, each of which consisted of two shares of common stock and a warrant to purchase one share of common stock. Each unit was priced at $2.00. The warrants are exercisable at $1.25 per share, exercisable for a period of five years from the date of issuance. New England Partners was granted piggyback registration rights to participate in the registration of the securities purchased in the private equity placement, which was completed in January 2001. The registration became effective August 28, 2002. Other terms and conditions were set forth in the definitive documents.

On January 31, 2001, the Company completed a private equity placement and raised $2,395,000. Proceeds were raised through the sale of units, each of which consisted of one share of common stock and a warrant to purchase one share of common stock. Each unit was priced at $1.00. The warrants are exercisable at $2.25 per share, valid for a period of three years from the date of issuance. Notwithstanding the foregoing, if the fair market value of one share of common stock of the Company is equal to or greater than $3.50 for twenty consecutive days during the term of the warrant, the Company has the right to demand that the

11

Table of Contents

holder exercise the warrant within a 30-day period. Failure of the holder to exercise the warrant within thirty days would cause the warrant to become void and the holder would lose all rights that it has with respect to the warrant. In accordance with the Securities Act of 1933, as amended, the Company filed a registration statement for the registration of the sale by the investors of their Company securities on April 12, 2001. The registration became effective December 27, 2001. Other terms and conditions were set forth in the definitive documents.

On June 30, 1998, the Company and Webster Bank entered into a Commercial Revolving Loan, Term Loan, Line of Credit and Security Agreement and related financing documents and agreements, with amendments to certain of such documents entered into on each of November 30, 1999, June 30, 2001 and December 31, 2001 (the “Webster Facility”).

The Webster Facility includes a revolving loan now for borrowings up to the lesser of (a) $5,000,000 or (b) an amount equal to the aggregate of (1) 85% of the eligible accounts receivable plus (2) 30% of eligible inventory provided, however, that at no time shall 85% of eligible accounts receivable be less than 50% of the outstanding revolver balance. The termination date of the revolving loan is December 31, 2003. In connection with the amendment to the Webster Facility entered into on December 31, 2001, several existing term loans totaling $1,728,490 were refinanced into a single term loan, which is due December 31, 2005. The Webster Facility includes an equipment loan line of credit that provides for equipment financing up to the lesser of $1,000,000 or 75% of the purchase price for eligible equipment through December 31, 2002. At December 31, 2002, advances of $276,000 had been taken on the equipment line of credit. The Company, on January 1, 2003, converted amounts borrowed under the equipment line of credit to a term loan. The equipment loan line of credit may be extended through December 31, 2003, at Webster Bank’s option. At March 31, 2003, an aggregate amount of approximately $1,681,000 was outstanding under the Webster Facility. The Webster Facility is secured by substantially all of the Company’s assets.

Interest on the revolving loan and equipment line of credit is variable based on LIBOR plus 2.5%. Interest on the outstanding term loan from December 31, 2001 is at a fixed rate of 7.55% per annum. Interest on the equipment advance converted January 1, 2003, to a term loan is at a variable rate based on LIBOR plus 2.5%.

In addition, the Webster Facility contains various restrictive covenants, including, among others, limitations on encumbrances and additional debt, prohibition on the payment of dividends or redemption of stock (except in connection with certain existing put rights), restrictions on management/ownership changes, and required compliance with specified financial ratios.

The Company has in the past grown through acquisitions (including the acquisition of Wire Solutions and Raychem Corporation’s nickel titanium product line). As part of its continuing growth strategy, the Company expects to continue to evaluate and pursue opportunities to acquire other companies, assets and product lines that either complement or expand the Company’s existing businesses. The Company intends to use available cash from operations and authorized but unissued common stock to finance any such acquisitions.

The Company has requirements to fund plant and equipment projects to support the expected increased sales volume of Shape Memory Alloys (SMAs) and superelastic materials during the fiscal year ending June 30, 2003, and beyond. The Company expects that it will be able to pay for these expenditures through a combination of existing working capital surplus, cash flow generated through operations and increased borrowings. The largest risk to the liquidity of the Company would be an event that caused an interruption of cash flow generated through operations, because such an event could also have a negative impact on the Company’s ability to access credit. The Company’s current dependence on a limited number of products and customers represents the greatest risk to regular operations.

In connection with a December 1994 subordinated debt financing, the Company granted Connecticut Innovations, Incorporated (“CII”), at the time the holder of both common stock and warrants of the Company, a “put” right if at any time before the earlier of June 28, 2006 and the date on which CII ceases to hold at least 35% of the common stock underlying the convertible securities originally issued to it, the Company ceases to (a) maintain its corporate headquarters and all of its product business operations in the State of Connecticut (including the assembly of all products to be sold to U.S. Surgical Corporation), excluding the Company’s components and sub-assembly business acquired from Raychem, (b) base its president and chief executive officer, a majority of its senior executives, and all of its administrative, financial, research and development, marketing and customer service staff relating to its product business (subject to the same inclusions and exclusions as clause (a)) in the State of Connecticut, (c) conduct all of its operations relating to its product business directly or through subcontractors and through licensed operations in the State of Connecticut (subject to the same inclusions and exclusions as clause (a)), and (d) maintain its principal bank accounts with banks located in the State of Connecticut (provided, however, that assets, revenues, employees, operations and bank accounts attributable to any entity acquired by the Company shall not be considered when determining if the Company has satisfied such requirements so long as such entity (1) was acquired in an arm’s length transaction, (2) was not an affiliate of the Company and was not controlled by an affiliate of the Company prior to such acquisition, and (3) had been in existence and operating as a business for at least one year at the time of the acquisition). Upon CII’s exercise of its put, the Company shall be obligated to purchase from CII all the Company’s Common Stock then owned by CII and underlying warrants

12

Table of Contents

then owned by CII at a price equal to the greater of the then current market price of the Company’s common stock or $2.00 per share, less, in either event, the aggregate amount of unpaid exercise prices of all warrants put to the Company by CII. Using $2.00 as the put price per share, which exceeds the market price for the Company’s common stock on March 31, 2003, the aggregate put price that would have to be paid by the Company if the put were exercised would be approximately $2.19 million. To the extent that the current market value of the Company’s common stock exceeds $2.00 per share at any time, the put price would be greater. If CII were to have the right to put its securities and were to choose to exercise that right, it would have a serious adverse effect on the Company’s liquidity and the Company would most likely have to seek equity financing to be able to meet its obligations to CII. However, the Company believes that it has the ability to ensure that its operations do not move from Connecticut in a manner that would trigger CII’s put.

In addition to funding normal operations, the Company may be required to secure new facilities to house its west coast operations during the next two fiscal years. The cost of this move and associated relocation expenses would be substantial; however the Company believes that the combination of its borrowing facility and cash flow generated through operations will be sufficient to meet the Company’s total capital requirements. If funds available through these sources were not sufficient, then the Company would likely be forced to raise equity capital which could have a material adverse effect on the per share market price of the Company’s common stock.

ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4.    CONTROLS AND PROCEDURES

Within the 90 days prior to the date of this report, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s principal executive officer and principal financial officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. Based upon that evaluation, the Company’s principal executive officer and principal financial officer concluded that the Company’s disclosure controls and procedures are effective in timely alerting them to material information required to be included in the Company’s periodic SEC reports. It should be noted that the design of any system of controls is based in part upon certain assumptions, and there can be no assurance that any design will succeed in achieving its stated goals.

In addition, we reviewed our internal controls, and there have been no significant changes in the Company’s internal controls or in other factors that could significantly affect those controls subsequent to the date of their last evaluation.

PART II — OTHER INFORMATION

Certain statements in this Quarterly Report on Form 10-Q that are not historical fact, as well as certain information incorporated herein by reference, constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties and often depend on assumptions, data or methods that may be incorrect or imprecise. The Company’s future operating results may differ materially from the results discussed in, or implied by, forward-looking statements made by the Company. Factors that may cause such differences include, but are not limited to, those discussed below and the other risks detailed in the Company’s other reports filed with the Securities and Exchange Commission.

Forward-looking statements give our current expectations or forecasts of future events. You can usually identify these statements by the fact that they do not relate strictly to historical or current facts. They often use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results.

Any or all of our forward-looking statements in this Quarterly Report on Form 10-Q and information incorporated by reference may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Many factors mentioned in this discussion—for example, product competition and the competitive environment—will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially. The Company undertakes no obligation to revise any of these forward-looking statements to reflect events or circumstances after the date hereof.

13

Table of Contents

Other Factors That May Affect Future Results

14

Table of Contents

ITEM 2.    CHANGES IN SECURITIES AND USE OF PROCEEDS

On April 10, 2003, the Company issued 62,500 warrants to purchase common stock, exercisable at $1.70 per share, valid for five years from the date of issue, to Trautman Wasserman & Co., Inc. as partial payment for investment banking services. Such issuance was exempt from the registration requirements of the Securities Act pursuant to Section 4(2) of the Securities Act.

ITEM 6.    EXHIBITS AND REPORTS ON FORM 8-K

(a)  EXHIBITS

(b)  REPORTS ON FORM 8-K

Current Report on Form 8-K filed January 24, 2003 (Items 5 and 7) (Relating to a press release announcing management’s estimate of earnings for the second quarter of fiscal year 2003).

Current Report on Form 8-K furnished February 14, 2003 (Item 9) (Relating to the furnishing of certifications to the SEC pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002).

15

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

16

Table of Contents

CERTIFICATIONS

I, James G. Binch, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Memry Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and

c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and

6. The registrant’s other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

17

Table of Contents

I, Robert P. Belcher, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Memry Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and

c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and

6. The registrant’s other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: May 15, 2003

18